CM AVM; CMAVM; DKFZp434N071; GAP; GTPase activating protein; GTPase-activating protein; OTTHUMP00000222390; OTTHUMP00000222391; OTTHUMP00000222392; OTTHUMP00000222393; p120GAP; p120RASGAP; PKWS; Ras GTPase-activating protein 1; RAS p21 protein activator (GTPase activating protein) 1; Ras p21 protein activator; RASA; RASA1; RASA1_HUMAN; RasGAP; Triphosphatase activating protein;
WB 1:500-1:2000, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000
Human, Mouse, Rat
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
RASA1 Antibody detects endogenous levels of total RASA1.
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
A synthesized peptide derived from human RASA1, corresponding to a region within C-terminal amino acids.
Observed Mol.Wt.: 116kDa.
Predicted Mol.Wt.: 117kDa.
In placental villi, detected only in the trophoblast layer (cytotrophoblast and syncytiotrophoblast). Not detected in stromal, endothelial or Hofbauer cells (at protein level).
The protein encoded by this gene is located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with basal cell carcinomas. Mutations also have been associated with hereditary capillary malformations (CM) with or without arteriovenous malformations (AVM) and Parkes Weber syndrome. Alternative splicing results in two isoforms where the shorter isoform, lacking the N-terminal hydrophobic region but retaining the same activity, appears to be abundantly expressed in placental but not adult tissues. [provided by RefSeq, May 2012]
10 20 30 40 50
MMAAEAGSEE GGPVTAGAGG GGAAAGSSAY PAVCRVKIPA ALPVAAAPYP
60 70 80 90 100
GLVETGVAGT LGGGAALGSE FLGAGSVAGA LGGAGLTGGG TAAGVAGAAA
110 120 130 140 150
GVAGAAVAGP SGDMALTKLP TSLLAETLGP GGGFPPLPPP PYLPPLGAGL
160 170 180 190 200
GTVDEGDSLD GPEYEEEEVA IPLTAPPTNQ WYHGKLDRTI AEERLRQAGK
210 220 230 240 250
SGSYLIRESD RRPGSFVLSF LSQMNVVNHF RIIAMCGDYY IGGRRFSSLS
260 270 280 290 300
DLIGYYSHVS CLLKGEKLLY PVAPPEPVED RRRVRAILPY TKVPDTDEIS
310 320 330 340 350
FLKGDMFIVH NELEDGWMWV TNLRTDEQGL IVEDLVEEVG REEDPHEGKI
360 370 380 390 400
WFHGKISKQE AYNLLMTVGQ VCSFLVRPSD NTPGDYSLYF RTNENIQRFK
410 420 430 440 450
ICPTPNNQFM MGGRYYNSIG DIIDHYRKEQ IVEGYYLKEP VPMQDQEQVL
460 470 480 490 500
NDTVDGKEIY NTIRRKTKDA FYKNIVKKGY LLKKGKGKRW KNLYFILEGS
510 520 530 540 550
DAQLIYFESE KRATKPKGLI DLSVCSVYVV HDSLFGRPNC FQIVVQHFSE
560 570 580 590 600
EHYIFYFAGE TPEQAEDWMK GLQAFCNLRK SSPGTSNKRL RQVSSLVLHI
610 620 630 640 650
EEAHKLPVKH FTNPYCNIYL NSVQVAKTHA REGQNPVWSE EFVFDDLPPD
660 670 680 690 700
INRFEITLSN KTKKSKDPDI LFMRCQLSRL QKGHATDEWF LLSSHIPLKG
710 720 730 740 750
IEPGSLRVRA RYSMEKIMPE EEYSEFKELI LQKELHVVYA LSHVCGQDRT
760 770 780 790 800
LLASILLRIF LHEKLESLLL CTLNDREISM EDEATTLFRA TTLASTLMEQ
810 820 830 840 850
YMKATATQFV HHALKDSILK IMESKQSCEL SPSKLEKNED VNTNLTHLLN
860 870 880 890 900
ILSELVEKIF MASEILPPTL RYIYGCLQKS VQHKWPTNTT MRTRVVSGFV
910 920 930 940 950
FLRLICPAIL NPRMFNIISD SPSPIAARTL ILVAKSVQNL ANLVEFGAKE
960 970 980 990 1000
PYMEGVNPFI KSNKHRMIMF LDELGNVPEL PDTTEHSRTD LSRDLAALHE
1010 1020 1030 1040
ICVAHSDELR TLSNERGAQQ HVLKKLLAIT ELLQQKQNQY TKTNDVR
Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1.
The N-terminus is blocked.Phosphorylated by SRC and LCK. The phosphorylation SRC inhibits its ability to stimulate the Ras-GTPase activity, whereas phosphorylation by LCK does not display any effect on stimulation activity.
Interacts with SQSTM1. Interacts with SPSB1; the interaction does not promote degradation. Interacts with CAV2 (tyrosine phosphorylated form). Directly interacts with NCK1. Interacts with PDGFRB (tyrosine phosphorylated). Interacts (via SH2 domain) with the 'Tyr-9' phosphorylated form of PDPK1.
Tips: For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
This product is for research use only. Not for use in diagnostic or therapeutic procedures.